Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

Video

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma (HCC).

The field of immunotherapy in HCC is moving extremely fast, Abou-Alfa says. There is quite a bit of evidence showing the expression of PD-1 and PD-L1 expression, as well as other markers for checkpoint inhibitors.

CheckMate-040, looking at nivolumab (Opdivo) in patients with HCC, showed a continued response rate of 22%. Based on this data, CheckMate-459, a study of nivolumab versus sorafenib (Nexavar), is now ongoing in the first-line setting.

Along that same line, the argument of whether to use checkpoint inhibitors in HCC is still unclear. For that purpose, a study of second-line pembrolizumab versus best supportive care is currently ongoing.

In addition, there is data suggesting that the combination of checkpoint inhibitors may be valuable in this disease, Abou-Alfa says.

Related Videos
Ilyas Sahin, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania